News
Hosted on MSN1mon
Sanofi to Acquire Blueprint Medicines for $9.1 Billion - MSNSanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) soared 26.5% after Sanofi (NASDAQ:SNY) revealed plans to acquire the biopharmaceutical company in a deal valued at approximately $9.5 billion. The ...
Paris and Cambridge, MA. June 2, 2025 . Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and ...
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology By Blueprint Medicines, Sanofi Jun 2, 2025 Updated Jun 2, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results